Extended Data Table 5 Inhibition titres (EC50) of RAY1216 and PF-07321332 in SARS-CoV-2 replicon assays

From: Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir

  1. The EC50 values are shown as mean ± SD (n = 3) for three biologically independent SARS-CoV-2 replicon assay experiments; fold changes relative to EC50 values determined against the replicon encoding WT Mpro are shown in the parentheses.
  2. Source data
Back to article page